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Abstract
Background:  Veno-arterial extracorporeal membrane oxygenation (ECMO) is a common
modality of circulatory assist device used in children. We assessed the outcome of children who
had ECMO following repair of congenital cardiac defects (CCD) and identified the risk factors
associated with hospital mortality.
Methods: From April 1990 to December 2003, 53 patients required ECMO following surgical
correction of CCD. Retrospectively collected data was analyzed with univariate and multivariate
logistic regression analysis.
Results: Median age and weight of the patients were 150 days and 5.4 kgs respectively. The
indications for ECMO were low cardiac output in 16, failure to wean cardiopulmonary bypass in
13, cardiac arrest in 10 and cardio-respiratory failure in 14 patients. The mean duration of ECMO
was 143 hours. Weaning off from ECMO was successful in 66% and of these 83% were survival to
hospital-discharge. 37.7% of patients were alive for the mean follow-up period of 75 months. On
univariate analysis, arrhythmias, ECMO duration >168 hours, bleeding complications, renal
replacement therapy on ECMO, arrhythmias and cardiac arrest after ECMO were associated with
hospital mortality.
On multivariate analysis, abnormal neurology, bleeding complications and arrhythmias after ECMO
were associated with hospital mortality. Extra and intra-thoracic cannulations were used in 79%
and 21% of patients respectively and extra-thoracic cannulation had significantly less bleeding
complications (p = 0.031).
Conclusion: ECMO provides an effective circulatory support following surgical repair of CCD in
children. Extra-thoracic cannulation is associated with less bleeding complications. Abnormal
neurology, bleeding complications on ECMO and arrhythmias after ECMO are poor prognostic
indicators for hospital survival.
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Background
Mechanical circulatory support plays a critical role in the
management of medically refractory post cardiotomy cir-
culatory failure. Various circulatory assist devices like Intra
aortic balloon pump (IABP), Ventricular assist devices
(VAD) and Venoarterial Extracorporeal membrane oxy-
genation (VA-ECMO) have been successfully used in post-
cardiotomy cardiogenic shock [1-3]. VA-ECMO is the
most commonly used therapy, especially in paediatric
patients, following repair of congenital cardiac defects.
This is due to the advantage of provision of pulmonary as
well as cardiac support by VA-ECMO and also ready avail-
ability and familiarity of ECMO circuits in pediatric inten-
sive care units (PICU). Moreover other types of circulatory
assist devices have their own limitations in pediatric use
[1].
The first application of ECMO as a cardiac support follow-
ing a palliative repair of congenital heart disease in a pedi-
atric patient was done by Baffes et al in 1970 [4]. Over the
past decade, the number of children successfully treated
by ECMO has increased gradually[3,5-9]. Since the prac-
tice and outcome of ECMO varies widely among the dif-
ferent centers around the world, we studied the long-term
outcome of children who had circulatory support with
VA-ECMO following repair of congenital heart defects in
our institution, with a view to identify the possible risk
factors associated with hospital mortality. We also
explored the relationship between the type of cannulation
and bleeding complications during ECMO support.
Methods
From April 1990 to December 2003, a total of fifty-three
patients required VA ECMO following the surgical correc-
tion of congenital cardiac defects in our institution, Glen-
field Hospital U.K. This represents 3.2% of total number
of congenital heart operations performed using cardiopul-
monary bypass during this period. Data was collected ret-
rospectively from patient's medical records, operative
reports, cardiac catheterization laboratory database,
ECMO department and PICU database. Follow-up infor-
mation was obtained from outpatient clinic and tele-
phone enquiry with patient's general practitioner. Patient
characteristic and diagnosis were shown in Table 1.
Definitions
Low cardiac output is defined as persistent hypotension,
oliguria (urine output < 0.5 ml/kg/hr) with clinical signs
of tissue hypoperfusion despite maximum inotropic sup-
port. (Combination of dopamine, adrenaline, milrinone
or enoximone and noradrenaline or vasopressin). In this
study the term cardiorespiratory failure refers to severe res-
piratory failure leading to refractory hypoxemia resulting
in cardiac dysfunction. Mechanical complications were
complications related to ECMO circuit such as clot in the
bladder or oxygenator failure.
Bleeding complications is defined as uncontrolled medi-
astinal bleeding despite correction of coagulopathy
requiring surgical intervention. Abnormal neurology is
defined as clinical signs of neurological dysfunction with
definite radiological findings like cerebral bleeding or inf-
arct on computerized tomographic scan of brain. Arrhyth-
mias after ECMO support refer to the occurrence of non-
sinus rhythm anytime after withdrawal of ECMO support.
The term sepsis was defined as clinical evidence of sepsis
with positive microbiology.
ECMO circuit design
The ECMO circuit consists of a venous cannula draining
the blood by gravity to a compliant 60 ml silicon bladder,
which is a servo regulating venous return monitor. A roller
pump (Sorin Biomedical, New haven, West Sussex, UK)
propels the blood from the bladder to an appropriately
sized poly-methoxy pentane membrane oxygenator
(Medos, Stolberg, Germany) with in-built heat exchanger
(Betta-Tech controls, Milton Keynes, UK). Avecor silicone
membrane oxygenators (Avecor Cardiovascular Products,
Plymouth, Minnesota, USA) were used till 2000. The oxy-
genated blood from the oxygenator is returned to the
patient through an arterial cannula. There is a connecting
bridge between arterial and venous line of the ECMO cir-
cuit (Figure 1). All the patients in this study were sup-
ported by VA ECMO according to our published protocol
[10].
Patient management during ECMO support
Anticoagulation
Adequate anticoagulation was achieved by heparin
sodium administration at a dose of 30–60 u/kg/hr to
maintain an activated clotting time of 180 to 200 sec.
Platelet count and fibrinogen were kept greater than
100,000/μl and 1 g/L respectively. Hemoglobin was main-
tained above 13 g/dl in all the patients. ACT and coagula-
tion parameters were usually checked hourly and 8th
hourly respectively. From 2002 onwards we changed the
ACT parameter to target between 160 to 180 seconds
because of use of Actalyke Max ACT system [11].
Circulatory support
The primary goal of post cardiotomy ECMO support is to
restore and maintain optimal tissue perfusion during
myocardial recovery. ECMO flows were kept maximum,
usually 150 ml/kg/min, as soon as the initiation of sup-
port and continued till satisfactory metabolic correction
was obtained. Minimal inotropic support was continued
during ECMO support (Dopamine 5–8 mcg/kg/min, Mil-
rinone 0.25–0.50 mcg/kg/min) to facilitate left ventricu-
lar (LV) emptying against increased afterload and alsoJournal of Cardiothoracic Surgery 2007, 2:4 http://www.cardiothoracicsurgery.org/content/2/1/4
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helps to prevent overdistension of LV. Milrinone reduces
the systemic vascular resistance thereby it attenuates the
effect of increased afterload caused by ECMO support.
One of the issues with ECMO for biventricular support is
increasing LV end diastolic pressures and distension due
to inadequate un-preloading of LV. Cardiac function was
regularly assessed by echocardiograph (ECHO) with min-
imal ECMO flow. Atrial septostomy or left ventricular
vent was used if there was evidence of LV distension.
Patients were carefully assessed for adequacy of intracar-
diac repair by ECHO and where necessary by cardiac cath-
eterization whilst on ECMO.
Ventilatory support
Once the condition of the patient was stabilized on
ECMO, ventilatory settings were reduced to minimum.
For the minimal setting, positive end-expiratory pressure
was set at 5–10 cm H2O, peak inspiratory pressures were
reduced to 20 cm H2O respiratory rate was set at 10/min
and the inspired oxygen fraction was reduced to 40%.
Since arterial oxygen content does not reflect the true pic-
ture of systemic hypoxia, mixed venous oxygen saturation
was maintained between 70–85% during the ECMO sup-
port.
Fluid management
The patients were usually intravascularly volume over-
loaded so as to optimize of atrial filling pressure and
maintain adequate cardiac output during the period of
resuscitation. Once the ECMO was instituted, negative
fluid balance was maintained in order to decrease the pul-
monary intersitial edema. Diuretics were used to facilitate
urine output of at least 2–3 ml/kg/hr. If the patient has
persistent oliguria (Impending acute renal failure) despite
diuretics, early institution of continuous venovenous
hemofiltration (CVVH) along with ECMO support was
employed.
Weaning
Full ECMO support was provided for minimum of 48 to
96 hours for almost all the patients. If the condition of
patient improved to a satisfactory level, the flows were
gradually reduced at hourly intervals over a 12 to 24 hour
period. Once the patient is hemodynamically stable on
minimal ECMO flow (30 ml/kg/min) with good recovery
of myocardial contractility as evidenced by ECHO,
patients were trailed off from ECMO support. If patient is
successfully trailed off from ECMO, decannulation was
done immediately and the cervical vessels were tied off
during decannulation in all the patients.
Statistical analysis
Univariate and multivariate analysis was performed using
peri ECMO variables with Genstat Release version-6.1
(VSN International, Oxford, UK) statistical package. Vari-
ables included in the analysis are explained in Table 2.
Table 1: Patient characteristics and diagnosis
Variables Survivors Non survivors Total
Male 15 14 29
Female 14 10 24
Median Age 142 days 180 days -
Median Weight 6 kg 5.2 kg -
Mean duration of ECMO 94 hr 164 hr -
Anatomical Diagnosis
Tetralogy of Fallot's (TOF) 4 5 16
TOF with additional lesionsa 25
Transposition of great arteries (TGA) 5 2 10
TGA with additional lesionsb 12
Ventricular septal defects (VSD) 2 1 6
VSD with additional lesions c 2 1
Total anomalus pulmonary venous drainage 2 2 4
Atrioventricular septal defect (AVSD) 2 2 4
Truncus arteriosus 3 1 4
Single ventricle heart 2 1 3
Other diagnosisd 42 6
"a" – Absent pulmonary valve, pulmonary atresia, right pulmonary artery stenosis, left pulmonary artery stenosis, pulmonary artery stenosis with 
bilateral aortopulmonary collaterals, multiple VSD, anomalus left anterior descending artery (LAD)
"b" – ASD and VSD, AVSD with hypoplastic arch, VSD with left ventricular outflow tract obstruction (LVOTO)
"c" – Coarctation of aorta, right ventricular outflow tract obstruction, ASD with bilateral superior vena cava
"d" – LVOTO, LVOTO with interrupted arch, pulmonary atresia with Ebstein anomaly, double outlet right ventricle with pulmonary atresia, 
anomalous LAD with myocardial infraction, pulmonary regurgitation with tricuspid anomalyJournal of Cardiothoracic Surgery 2007, 2:4 http://www.cardiothoracicsurgery.org/content/2/1/4
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Analysis of the simple association, 2 × 2 table of associa-
tion of death/survival classified by all the other binary fac-
tors, has been done using a chi-squared test and was
checked by using Fisher exact test. Continuos variables
were examined by logistic regression.
Results
Patient's age ranged from 1 to 3960 days (Median age: 150
days). Median weight of patient was 5.4 kg (range: 2.4 to
30 kg). Mean duration of ECMO support was 143 hours
(range: 8 to 460 hours). Primary diagnosis in these
patients were Tetralogy of Fallot's (TOF) with associated
lesions in 16 patients, Transposition of Great Arteries
(TGA) with associated lesions in 10 patients, VSD with
associated lesions in 6 patients, Truncus arteriosus in 4
patients including one patient with DiGeorge syndrome,
Univentricular heart in 3 patients [rudimentary right ven-
tricle with VSD, double inlet left ventricle with pulmonary
atresia, pulmonary atresia with intact ventricular septum],
Total anomalous pulmonary venous drainage in 4
patients and AVSD in 3 patients. The remaining six
patients had the following various lesions: Left ventricular
outflow tract obstruction (LVOTO), LVOTO with inter-
rupted arch, pulmonary atresia with Ebstein's anomaly,
double outlet right ventricle with pulmonary atresia,
anomalous left coronary artery with myocardial infraction
and pulmonary regurgitation with tricuspid anomaly. All
the associated lesions were described in Table 1 various
operative procedures for these patients and survival were
illustrated in Table 3.
Indications
The indications for ECMO support were a) low cardiac
output (n = 16), b) failure to wean from cardiopulmonary
bypass (n = 13), c) cardiac arrest in PICU (n = 10) and d)
cardiorespiratory failure (n = 14).
Overall outcome and survival based on indications
Thirty-five patients (66%) were successfully weaned off
from ECMO support. Twenty-nine patients (54%) sur-
vived to hospital discharge. Twenty patients (37.7%) were
alive after a mean follow up period of 75 months. Surviv-
VA-ECMO circuit model Figure 1
VA-ECMO circuit model.Journal of Cardiothoracic Surgery 2007, 2:4 http://www.cardiothoracicsurgery.org/content/2/1/4
Page 5 of 9
(page number not for citation purposes)
als to hospital discharge based on their indication for
ECMO support were as follows: 75%(12/16) in low car-
diac output patients, 54% (7/13) in failure to come off
CPB patients, 50% (5/10) in cardiac arrest patients and
36% (5/14) in cardiorespiratory failure patients.
Complications
Patient related complications such as bleeding and sepsis
are charted in Table 4. The details of mechanical compli-
cations related to circuit are as follows: Thirteen patients
(24%) had small blood clots identified in bladder box
and bridging tube and 7 patients (13%) had clots in oxy-
genator. Three patients (6%)had oxygenator failure
needed oxygenator changing and other two patients
(4%)had ECMO circuit failure requiring new circuit.
None of these mechanical complications were fatal.
Mortality
Twenty-four patients (45%) died in hospital, eighteen
patients (34%) died during ECMO support and six
patients (11%) died in hospital after withdrawal of
ECMO. About half of the patients died due to irreversible
multiorgan failure (29%) and neurological damage
(21%). Failed myocardial recovery (12%), hemorrhage
(17%) including pulmonary and gastrointestinal hemor-
rhage and other causes (21%) including profound sepsis
were responsible for the death of the remaining patients.
On univariate analysis the following factors were associ-
ated with increased hospital mortality: postoperative
arrhythmias, duration of ECMO more than 168 hours,
bleeding complications, requirement of renal replace-
ment therapy (RRT) on ECMO, arrhythmias and cardiac
arrest after ECMO support. On multivariate analysis,
arrhythmias after ECMO, bleeding complications and
abnormal neurology during ECMO were significantly
associated with hospital mortality. Comparatively extra-
thoracic cannulation had significantly less bleeding on
ECMO (p = 0.031)
Discussion
VA-ECMO is a partial cardiopulmonary support, which
can be offered to any patient with potentially reversible
cardiac, pulmonary or cardiopulmonary failure following
cardiotomy. Recent studies have proved that it can be suc-
cessfully used even after prolonged cardiopulmonary
resuscitation [12,13]. Compared to adult cardiac support
by VA-ECMO, the outcome of children who had VA-
ECMO following the correction of congenital cardiac
defect are very promising [3,9,14]. Interestingly there are
no universally accepted standardized well-established cri-
teria for indication and protocol to manage cardiac ECMO
patients [15]. Since a wide range of complex congenital
cardiac defects were supported by ECMO, there is consid-
erable variation in the results published by different cen-
tres and therefore it complicates the issue of interpreting
the published literature [15].
Achieving a successful outcome in this group of compli-
cated cardiac patients is affected by many factors such as
the timing of application, pre ECMO clinical status of
patients and indications for ECMO support. Majority of
published reports quotes that weaning from ECMO sup-
port as an outcome measures while some of them quotes
as survival to hospital discharge [5,7,12,13,16]. So far
only a few published reports have reported long-term as
Table 2: Univariate analysis of peri ECMO variables
Variables Survivors (N = 29) Non survivors (N = 24) p-Value
Age 589 days 452.5 days NS
Male sex 15 14 NS
Weight 8.4 kg 7.2 kg NS
Pre ECMO Metabolic acidosis 7.12 ± 0.07 7.08 ± 0.01 NS
Pre ECMO Arrhythmias 13 21 < 0.001
Cardiac arrest before cannulation 5 5 NS
Failure to wean from CPB 7 6 NS
Low cardiac output status 12 4 NS
Cardiorespiratory failure 5 9 NS
Bleeding complications 4 14 < 0.001
Use of RRT 10 20 < 0.001
Abnormal neurology 5 5 NS
Pulmonary complications 3 8 NS
Sepsis 3 6 NS
Mechanical complication of Circuit 10 15 NS
ECMO duration > 168 hrs 4 10 =0.024
Arrhythmias after ECMO support 9 22 =0.001
Cardiac arrest after ECMO support 6 16 < 0.001
CPB – Cardiopulmonary bypass; RRT – Renal replacement therapy.Journal of Cardiothoracic Surgery 2007, 2:4 http://www.cardiothoracicsurgery.org/content/2/1/4
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opposed to hospital survival[15,17,18]. In our study 66%
of patients were successfully weaned off from ECMO and
this compares well with the results of other experienced
centres [3,7,9]. In this cohort, 54% of patients survived to
hospital discharge, which is similar to other reports
[7,16]. Among the hospital-discharged patients 69% are
were alive and well for a mean follow up period of 75
months, this compares favorably with other published
series[17,18]. In other words, 37.7% of patients were
long-term survivors after post cardiotomy VA-ECMO sup-
port in this study. Most of the late deaths occurred a year
after discharge in the community since there was no post-
mortem examination carried out in these patients the
exact cause of deaths could not be identified. The pediatric
cardiologists followed almost all the long-term survivors
in the out patient clinic and they are doing well.
In this study survival to hospital discharge was better in
patients who had ECMO support for low cardiac output
compared to the other indications and all these patients
had ECMO in the PICU because of failure of all conven-
tional treatment modalities including induced hypother-
mia [19]. The duration of conventional treatment before
these patients were supported on ECMO was raging
between 2 to 48 hours (Mean 18.5 hours). In contrast to
some of the published literature, in this series the institu-
tion of ECMO in the operating theatre for patients that
had difficulties in coming off cardiopulmonary bypass
had survival of 54% [5,20,21]. Most of the patients had
complete surgical repair of their cardiac defects and in
patients with shunt dependent pulmonary circulation the
shunt was left open during ECMO support and this has
been shown to be an important factor in achieving better
survival in this group [22,23]. Even in the absence of a for-
mal rapid deployment system (Extra-corporeal cardiopul-
monary resuscitation program) the survival of patients
supported by ECMO following cardiac arrest were 50%
and this similar to other published reports [7,9,12,13].
Currently we are working to establish rapid deployment
ECMO system in our unit. Based on the anatomical diag-
nosis, patient with TOF had comparatively poor outcome
because majority of the patients in the non-survivor group
had complicated associated lesions like distal pulmonary
artery stenosis along with TOF (Table 1). Chaturvedi et al
also observed poor survival among the TOF patients in
their study with biventricular patients [24].
Factors affecting the hospital survival identified by 
univariate analysis
Rhythm disturbances can often result in hemodynamic
instability during the immediate postoperative period and
it is a major cause of morbidity and mortality. Arrhyth-
mias during the crucial period of myocardial recovery
should always raise the possibility of progressive cardiac
dysfunction or acute respiratory decompensation. Recur-
rent episodes of postoperative arrhythmias before the ini-
tiation of ECMO were significantly associated with the
hospital mortality in this study (p < 0.001). Most of the
arrhythmias were resistant to anti-arrhythmatic medica-
tions. Hoskote, A and collegues also found that refractory
tachydysrhythmia before initiation of ECMO support was
a risk factor for mortality in functional single ventricle
patients[25]. Extracorporeal life support has also been
used successfully for the treatment of supraventricular
tachycardia (SVT) as well [26].
Some of these patients required longer duration of
mechanical support to get adequate myocardial recovery.
Table 4: Complications during ECMO support
Complications
Bleeding 36%
Neurological 19%
Sepsisa 17%
Renal 57%
Pulmonaryb 21%
Mechanicalc 47%
"a" – Chest infection (9.4%), Intraabdominal sepsis (3.7%), Sternal 
wound infection (1.8%), Cannulation site infection (1.8%).
"b" – Pneumothorax (11.3%), Pleural effusion (9.4%)
"c" – Mechanical complications of the ECMO circuit
Table 3: Operative procedures and survival
Name of operation Total number Survival
Repair of TOF +/- additional procedures 16 (9+7) 37%
Arterial switch +/- additional procedures 10 (7+3) 60%
VSD repair +/- additional procedures 6 (3+3) 67%
Complete AVSD repair +/- additional procedures 4 (2+2) 50%
Truncus arteriosus repair 4 75%
Repair of TAPVD 4 50%
Modified Fontan procedure 3 67%
Othersa 66 7 %
"a" – Repair of LVOT (Redo), Repair of LVOT with interrupted arch, Reimplant of left coronary (Takeuchi tunnel procedure), Left modified Blalock 
Taussig shunt, Repair of DORV and RVOT, Pulmonary and tricuspid valve repairJournal of Cardiothoracic Surgery 2007, 2:4 http://www.cardiothoracicsurgery.org/content/2/1/4
Page 7 of 9
(page number not for citation purposes)
Severe initial myocardial insult before the initiation of
ECMO support could be the likely reason for prolonged
myocardial recovery time. In this study it was found that
one fourth of patients (26.4%) required ECMO support
over a week and four patients (7.54%) needed more than
two weeks. Statistically it was observed that duration of
ECMO more than 168 hours is clearly associated with
hospital mortality (p < 0.001). Previous studies have dem-
onstrated the fact that if the patient needed a longer dura-
tion of ECMO support, their survival tends to be
poor[3,7,22,24]. In fact, Duncan et al observed poorer
outcomes even in the children who were supported by
VAD for more than 48 hours[7].
More than half of patients (57%) required CVVH in this
study, the need of RRT on ECLS in these patients implies
the severity of secondary organ dysfunction. The majority
of these patients were treated by continuous venovenous
hemofiltration while few of them had peritoneal dialysis.
In this cohort, requirement of renal replacement therapy
during ECMO support was identified as a significant risk
factor for hospital mortality (p < 0.001). Kolovos et al also
demonstrated that the post cardiotomy ECMO supported
children requiring hemofiltration were five times more
likely die than other patients [9].
Factors affecting the hospital survival identified by 
multivariate analysis
The incidence of neurological complications during VA-
ECMO support varies from 22% to 31% [7,16,17]. In our
study total of ten patients (21%) had abnormal neurol-
ogy; three of them had cardiopulmonary resuscitation
(CPR) for more than 45 minutes before initiation of
ECMO. It is difficult to attribute ECMO support was the
reason for neurological complications in these 3 patients.
Kulik et al mentioned about thirty percent of patients with
neurological complication who had previous CPR before
ECMO, moreover neurological complications was one of
the reasons for withdrawal of ECMO support in their
study [27]. In our study Four patients had intracranial
bleeding (8%), Two patients had localized cerebral
infracts (4%), Three patients had hypoxic ischemic
encephalopathy (5%) and one patient had cerebral atro-
phy (2%). we found that abnormal neurology is one of
the variables strongly associated with hospital mortality
(p < 0.001). In this cohort only two of long-term survivors
had functional neurological deficit (Hemiperesis) where
as 39% of long-term survivors had neurological deficits in
Chow et al study [17]. They also found that CPR prior to
ECLS was a predictor of hospital death but whether there
is a relation between the CPR prior to ECLS and neurolog-
ical deficit is not clear in their study [17]. Where as
Chaturvedi and colleagues have proved that brain death
was very strongly associated with CPR before initiation of
ECMO [24].
Bleeding complications are an inevitable problem during
this life saving therapy. Heparin is not the only factor
responsible for bleeding in these patients since most of
them were bound to have altered homeostasis resulting in
deranged hemostasis. Mediastinal bleeding requiring sur-
gical reexploration was another risk factor significantly
affecting hospital survival in this group of patients (p <
0.001). In this study 36% of patients had intrathoracic
bleeding within 48 hours of initiation of ECMO. Once the
abnormal coagulation was corrected with Fresh frozen
plasma, Cryoprecipitate and platelet transfusion. Heparin
was withheld temporarily in these patients to control the
bleeding. Aprotinin and AMICAR were also used. Failure
of these conservative measures resulted surgical reexplora-
tion. Upon reopening the chest almost more than 90% of
patient no surgical source of bleeding was found. Their
sternum left open with skin closed for 24 to 48 hours.
Majority of them had more than one surgical reexplora-
tion. Meliones JN and collegues were also identified medi-
astinal bleeding as risk factor for mortality in their review
of extracorporeal life support organization registry [28].
The initiation of ECMO leads to an initial worsening of
coagulopathy in these sick patients[29] Whether using
heparin coated extra-corporeal circuit [30] or using
recombinant Factor VIIa would make any difference in
these patients needs further evaluation[31]. In fact, Aho-
ran et al reported all the patients who had transthoracic
ECMO cannulation needed surgical reexploration for
bleeding but the actual incidence surgical bleeding in that
group was not mentioned [3]. The relationship between
type of cannulation and bleeding complications in our
study will be discussed below.
Rhythm disturbances after withdrawal of ECMO are
potentially serious complications adversely affecting the
outcome. Occurrence of arrhythmias in these patients
may be due to electrolyte abnormalities, metabolic distur-
bances (acidosis) and poor myocardial recovery despite
maximal ECMO support. Nine patients (29%) developed
recurrent arrhythmias after withdrawal of ECMO. Six
patients had SVT (Junctional ectopic tachycardia in five,
atrial flutter in one patient) and three patients had ven-
tricular tachycardia. These patients were treated with
appropriate anti-arrhythmatic medications and electro-
cardioversion. In this study arrhythmias after withdrawal
of ECMO support was identified as a risk factor for hospi-
tal mortality (p < 0.001). Becker et al found that cardio-
vascular complications including arrhythmias have
significant negative impact on the survival of the ECMO
patients [32]. Cardiac complications were also noted to be
one of the major causes for mortality in the ELSO registry
data [28]. Identifying these high-risk patients with poor
myocardial recovery and address them with bridge to
transplant or recovery might improve the survival [33].Journal of Cardiothoracic Surgery 2007, 2:4 http://www.cardiothoracicsurgery.org/content/2/1/4
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Cannulation technique
Appropriate size of the cannula is the crucial factor in pro-
viding the support by extracorporeal circuit. In these
patients even if cannulation were done in the operating
theatre, the preferred type of cannulation was cervical. The
cannulation technique has been described previously
[34]. Seventy nine percent of patients were cannulated via
the internal jugular vein and carotid artery while only
twenty one percent had transthoracic cannulation. In this
study we identified that the extrathoracic cannulation was
associated with significantly less bleeding complications
(p = 0.031). Duncan and colleagues also found this fact in
their study involving both surgical and non-surgical
patients [7]. Moreover the relationship between cannula-
tion type and the abnormal neurology was assessed using
Fisher's exact test and was not found to be significant (p =
0.67).
Study limitations
This is a retrospective study from a single centre. Sample
size is relatively small and only three patients with univ-
entricular hearts were involved. Post cardiotomy paediat-
ric patients following surgical correction of congenital
cardiac defect who required VA-ECMO only were
included in this study. Some laboratory variables like lac-
tate could not be included in the analysis because of
incomplete data. In spite of the limitations, our study is
one of the few reported a long-term survival of pediatric
patients following VA-ECMO support.
Conclusion
Our long-term data confirms that Veno-arterial ECMO
can provide an effective mechanical circulatory support
following adequate surgical repair of CCD in children.
Extra thoracic cannulation is associated with less bleeding
complications during ECMO support. Abnormal neurol-
ogy, bleeding complications on ECMO and arrhythmias
after ECMO support, are poor prognostic indicators for
hospital survival.
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